BioMed Research International

BioMed Research International / 2020 / Article

Review Article | Open Access

Volume 2020 |Article ID 7136075 |

Fahmi Shaher, Hongbin Qiu, Shuqiu Wang, Yu Hu, Weiqun Wang, Yu Zhang, Yao Wei, Hisham AL-ward, Mahfoudh A. M. Abdulghani, Sattam Khulaif Alenezi, Salem Baldi, Shaobo Zhou, "Associated Targets of the Antioxidant Cardioprotection of Ganoderma lucidum in Diabetic Cardiomyopathy by Using Open Targets Platform: A Systematic Review", BioMed Research International, vol. 2020, Article ID 7136075, 20 pages, 2020.

Associated Targets of the Antioxidant Cardioprotection of Ganoderma lucidum in Diabetic Cardiomyopathy by Using Open Targets Platform: A Systematic Review

Academic Editor: Miroslav Pohanka
Received12 Apr 2020
Revised05 Jun 2020
Accepted09 Jun 2020
Published25 Jul 2020


Even with substantial advances in cardiovascular therapy, the morbidity and mortality rates of diabetic cardiomyopathy (DCM) continually increase. Hence, a feasible therapeutic approach is urgently needed. Objectives. This work is aimed at systemically reviewing literature and addressing cell targets in DCM through the possible cardioprotection of G. lucidum through its antioxidant effects by using the Open Targets Platform (OTP) website. Methods. The OTP website version of 19.11 was accessed in December 2019 to identify the studies in DCM involving G. lucidum. Results. Among the 157 cell targets associated with DCM, the mammalian target of rapamycin (mTOR) was shared by all evidence, drug, and text mining data with 0.08 score association. mTOR also had the highest score association 0.1 with autophagy in DCM. Among the 1731 studies of indexed PubMed articles on G. lucidum published between 1985 and 2019, 33 addressed the antioxidant effects of G. lucidum and its molecular signal pathways involving oxidative stress and therefore were included in the current work. Conclusion. mTOR is one of the targets by DCM and can be inhibited by the antioxidative properties of G. lucidum directly via scavenging radicals and indirectly via modulating mTOR signal pathways such as Wnt signaling pathway, Erk1/2 signaling, and NF-κB pathways.

1. Introduction

Cardiovascular complications are associated with diabetes and lead to high mortality [1, 2]. Diabetic cardiomyopathy (DCM) is one of the main causes of heart injury and death in patients with diabetes. A total of 1.6 million deaths worldwide are directly attributed to diabetes every year [3]. Independent of coronary artery disease, DCM has increased prevalence during the last two decades and is experienced by 55% of patients with diabetes [4]. With diabetes being a global epidemic, the number of patients with DCM has increased. For the last two decades, the number of people with diabetes worldwide has increased from 151 million in 2000 to 425 million in 2017 and is estimated to increase to 629 million by 2045 [5]. The risk of developing DCM is higher for patients with diabetes than that for those without diabetes [6] and increases 2 to 4 times for those with more than a 10-year span of diabetes [7, 8]. Once DCM has developed, reducing its morbidity and mortality is difficult even with pharmacological improvement in terms of regulating blood glucose and insulin sensitivity. Clinical and preclinical investigations have examined the complexity of the pathophysiological consequences of DCM.

Clinical studies in patients with DCM reported that the pathological remodeling of the heart, which is characterized by left ventricular concentric hypertrophy and perivascular and interstitial fibrosis commencing to diastolic dysfunction and extended contraction and relaxation [9, 10], shortens ventricular ejection and increases wall stiffness [11, 12]. The influence of the diabetic condition on heart and cardiomyocyte function has been experimentally evaluated.

DCM and cardiac dysfunction are initiated in diabetic-induced experimental animals from 2 to 12 weeks [13]. Streptozotocin-induced diabetes in mice leads to the morphological changes of heart tissues, interstitial collagen deposition, cardiac hypertrophy, fibrosis, and remarkable elevation of paracrine of angiotensin II level in myocardium and NADPH oxidase activities, which are considered the primary source of free radicals in the cardiomyocytes of diabetic heart [14]. Connective tissue growth factor mediates cardiac fibrosis in diabetes [13, 15]. In diabetic mice with cardiomyopathy, the expression of sarcoplasmic reticulum calcium ATPase and [Ca+2] ion transient is reduced [16]. Sarcoplasmic reticulum calcium ATPase is a primary cardiac isoform of calcium pump transporting calcium from cytoplasm to sarcoplasmic reticulum during diastolic relaxation [17].

Even with substantial advances in cardiovascular therapy, diabetic morbidity and mortality rate are continually increasing, and a feasible therapeutic approach for DCM is still lacking. Exploring the medication targets for DCM may further identify novel drugs and improve specific therapies for DCM. Therapeutic targets for DCM with natural resources are considered as one of the main reservoirs for drug discovery. Therefore, novel therapeutics for a range of targets must be developed to prevent DCM progression. This study identifies molecular target involvement and its association with DCM by using the Open Targets Platform (OTP) website established by Biogen, EMBL European Bioinformatics Institute, GlaxoSmithKline, and Wellcome Trust Sanger Institute. The OTP provides comprehensive and up-to-date data for drug molecular targets associated with relative diseases. Oxidative stress (OS) may be a key factor in the molecular and cellular mechanisms of diabetes-induced DCM [18]. Hence, targeting OS-related processes could be a promising therapeutic strategy for DCM.

Ganoderma (G.) lucidum, which is known in Chinese as “Lingzhi,” is a medicinal mushroom commonly used as a Chinese herbal medicine and the main ingredient in many conventional combinations or dietary supplements [19]. This name has been proposed by Petter Adolf Karsten from England in the late 19th century and has been applied in various places such as Asia, Africa, Oceania, and Europe [20]. Lingzhi has been widely cultivated in China and has a long history as a traditional Chinese medicine. Chinese G. lucidum exhibits high variability of basidioma morphology and more or less consistency in its microscopic characters, e.g., short clavate cutis elements, Bovista-type ligative hyphae, and strongly echinulated basidiospores [21]. G. lucidum also contains various bioactive compounds, such as flavonoids, ganoderic acid, phenolics, and polysaccharides [21], that can treat many chronic diseases including diabetes and its complications by counteracting OS. Preclinical studies reported the beneficial effects of G. lucidum against OS-induced diseases, its liver protection against CCl4-induced OS [22], skin protection against croton oil-induced lipid peroxidation in mice [23], and thymus and spleen protection against 5-fluorouracil-induced OS in mice [21]. This systematic review is aimed at discussing the potential cell targets and cardioprotective pathway of G. lucidum based on preclinical and clinical investigations.

2. Methods

The OTP website version 19.11 (OTP V 19.11) was used to prioritize and identify the targets associated with DCM. The OTP provides score and rank target-disease associations and integrates evidence from six resources, including genetics, genomics, transcriptomics, drugs, animal models, and scientific literature [24, 25]. Two main steps of searching were performed in December 2019. In the first step, the term “diabetic cardiomyopathy” was used, and all the targets associated with DCM were listed according to available evidence recorded through bioinformatic processing, including data evidence of drug, text mining, genetic association, somatic mutation, pathways and signals, RNA signal, and animal model. The resulting targets with the highest association with DCM from the first step were used to further search for evidence on G. lucidum cardioprotection.

This systematic review on the antioxidant activity of G. lucidum was described as follows. Abstracts published from 1985 to July 2019 were reported as guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [26] (Figure 1). The key terms used were G. lucidum and spore of G. lucidum. In this step, the studies were divided into seven 5-year periods to easily read and select related abstracts. The search was limited to studies published in English and Chinese languages. Inclusion criteria were as follows: studies must focus on (1) G. lucidum and its (2) antioxidant, antidiabetic, and cardioprotective activities. Exclusion criteria were as follows: studies focusing on (1) mushrooms other than G. lucidum and (2) not related to its antioxidant activities such as the botanical and genetic studies of G. lucidum.

3. Results

3.1. Targets Associated with DCM in Diabetes Integrated by OTP
3.1.1. DCM and Its Associated Targets

A total of 309 targets were associated with DCM based on evidence from drug and text mining data with overall association scores from 0.004 to 0.177 (Table 1, supplementary file (available here)). Among the selected drug data, only two targets, namely, carnitine palmitoyltransferase 1B (CPT1B) and 2 (CPT2) were associated with DCM with 0.1 score association. A total of 306 targets were identified from text mining. Only the mechanistic target of rapamycin kinase (mTOR) was common in both types of data. A total of 309 targets were expressed in 32 tissue organs including the heart and were involved in 19 pathway types (Table 2, supplementary file (available here)). Among these 309 targets, 155 were expressed in the heart tissues with overall association scores ranging from 0.007 to 0.177 (Table 1). Among the 19 pathways, 4 targets were included in autophagy (Table 2), namely, mTOR, beclin 1 (BECN1), parkin RBR E3 ubiquitin protein ligase (PRKN), and voltage-dependent anion channel 1 (VDAC1) with scores of 0.1, 0.06, 0.05, and 0.03, respectively.

Target nameTarget symbolAssociation score
Data types
Known drug
Data types

1Tripartite motif containing 55TRIM5500.1770.177
2Peroxisome proliferator-activated receptor alphaPPARA00.1170.117
3Mechanistic target of rapamycin kinaseMTOR0.10.0540.113
4Interleukin 6IL-600.1130.113
5Carnitine palmitoyltransferase 1BCPT1B0.10.0000.100
6Carnitine palmitoyltransferase 2CPT20.10.0000.100
7Tripartite motif containing 54TRIM5400.0810.081
8Nuclear factor, erythroid 2 like 2NFE2L200.0720.072
9Hydroxysteroid 11-beta dehydrogenase 1HSD11B100.0700.070
10Fibroblast growth factor 1FGF100.0700.070
11Colony-stimulating factor 3CSF300.0620.062
12Beclin 1BECN100.0620.062
13Cytochrome P450 family 2 subfamily J member 2CYP2J200.0610.061
14Angiotensin I-converting enzyme 2ACE200.0600.060
15Aldehyde dehydrogenase 2 family memberALDH200.0590.059
16Glycogen synthase kinase 3 betaGSK3B00.0570.057
18Toll-like receptor 2TLR200.0540.054
19Parkin RBR E3 ubiquitin protein ligasePRKN00.0540.054
21ST3 beta-galactoside alpha-2,3-sialyltransferase 4ST3GAL400.0520.052
22Peroxisome proliferator activated receptor gammaPPARG00.0520.052
23Corin, serine peptidaseCORIN00.0520.052
26Protein kinase D1PRKD100.0490.049
27PPARG coactivator 1 alphaPPARGC1A00.0480.048
28Vascular endothelial growth factor AVEGFA00.0480.048
29Insulin-like growth factor 1IGF100.0470.047
30CD36 moleculeCD3600.0470.047
31Nitric oxide synthase 3NOS300.0460.046
32Apolipoprotein A1APOA100.0440.044
33Gap junction protein alpha 1GJA100.0410.041
34Calsequestrin 2CASQ200.0410.041
37Cellular communication network factor 2CCN200.0400.040
38Matrix metallopeptidase 2MMP200.0400.040
40Fibroblast growth factor 2FGF200.0390.039
41BCL6 transcription repressorBCL600.0390.039
42Tax1-binding protein 1TAX1BP100.0380.038
43Solute carrier family 2 member 4SLC2A400.0380.038
44Rho-associated coiled-coil containing protein kinase 2ROCK200.0370.037
45NADPH oxidase 4NOX400.0360.036
46Mitogen-activated protein kinase 9MAPK900.0360.036
47Insulin-like growth factor 2IGF200.0360.036
48Angiotensin II receptor type 2AGTR200.0360.036
49Lipoprotein lipaseLPL00.0360.036
50Insulin receptorINSR00.0350.035
51Angiopoietin 1ANGPT100.0350.035
52Interleukin 33IL3300.0350.035
53Caveolin 3CAV300.0340.034
54Angiotensin I-converting enzymeACE00.0340.034
55Patatin-like phospholipase domain containing 2PNPLA200.0340.034
56ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2ATP2A200.0330.033
58Dimethylarginine dimethylaminohydrolase 2DDAH200.0320.032
59Xenotropic and polytropic retrovirus receptor 1XPR100.0320.032
60Vascular endothelial growth factor BVEGFB00.0320.032
61Phosphodiesterase 5APDE5A00.0310.031
62MAPK-activated protein kinase 2MAPKAPK200.0310.031
63Heat shock protein family E (Hsp10) member 1HSPE100.0310.031
64Sirtuin 2SIRT200.0310.031
65DIRAS family GTPase 3DIRAS300.0300.030
66SMAD family member 3SMAD300.0300.030
67Dual specificity phosphatase 5DUSP500.0300.030
68Kruppel-like factor 4KLF400.0300.030
69Ryanodine receptor 2RYR200.0290.029
71Estrogen related receptor gammaESRRG00.0280.028
73Peroxiredoxin 3PRDX300.0280.028
74Adrenoceptor beta 2ADRB200.0280.028
75Solute carrier family 9 member A1SLC9A100.0280.028
76Transglutaminase 2TGM200.0270.027
77Poly(ADP-ribose) polymerase 1PARP100.0270.027
78Insulin receptor substrate 1IRS100.0270.027
79Voltage dependent anion channel 1VDAC100.0260.026
80AKT serine/threonine kinase 1AKT100.0250.025
81Myocyte enhancer factor 2AMEF2A00.0250.025
82Dual specificity phosphatase 1DUSP100.0250.025
84Diacylglycerol kinase zetaDGKZ00.0240.024
85Death associated protein kinase 2DAPK200.0240.024
86Solute carrier family 25 member 4SLC25A400.0230.023
87SMAD family member 7SMAD700.0230.023
88Natriuretic peptide ANPPA00.0230.023
89Coiled-coil domain containing 47CCDC4700.0220.022
90Lipase E, hormone sensitive typeLIPE00.0220.022
92Arylsulfatase AARSA00.0210.021
93Nitric oxide synthase 2NOS200.0210.021
94Nuclear receptor subfamily 3 group C member 2NR3C200.0210.021
95Sirtuin 3SIRT300.0210.021
97Spindlin 1SPIN100.0200.020
98Serpin family E member 1SERPINE100.0200.020
99Tachykinin receptor 1TACR100.0200.020
100RNA binding fox-1 homolog 2RBFOX200.0200.020
101Fatty acid binding protein 4FABP400.0190.019
102Potassium voltage-gated channel subfamily H member 2KCNH200.0190.019
103Cell adhesion molecule 1CADM100.0190.019
105Nucleotide-binding oligomerization domain containing 1NOD100.0180.018
106Activating transcription factor 3ATF300.0180.018
107Vasoactive intestinal peptideVIP00.0180.018
108Egl-9 family hypoxia inducible factor 3EGLN300.0180.018
109Fibronectin 1FN100.0180.018
110Endothelin 1EDN100.0180.018
111C-C motif chemokine ligand 2CCL200.0180.018
112Solute carrier family 5 member 1SLC5A100.0180.018
113Fibrinogen-like 2FGL200.0170.017
114Monoamine oxidase AMAOA00.0170.017
115Sphingosine-1-phosphate receptor 1S1PR100.0170.017
116Signal transducer and activator of transcription 3STAT300.0170.017
117Toll-like receptor 3TLR300.0170.017
118Tripartite motif containing 63TRIM6300.0170.017
119TIMP metallopeptidase inhibitor 2TIMP200.0170.017
120Nerve growth factorNGF00.0170.017
121Natriuretic peptide receptor 2NPR200.0160.016
122Cyclin-dependent kinase inhibitor 1ACDKN1A00.0160.016
123Cathepsin DCTSD00.0160.016
124Thrombospondin 1THBS100.0150.015
125Kinase insert domain receptorKDR00.0150.015
126Serine/threonine kinase 11STK1100.0150.015
127Enolase 3ENO300.0150.015
128Gasdermin DGSDMD00.0150.015
129Cytochrome c, somaticCYCS00.0150.015
130Kallikrein B1KLKB100.0150.015
131TIMP metallopeptidase inhibitor 4TIMP400.0150.015
132Transforming growth factor beta 3TGFB300.0150.015
133Zinc finger and BTB domain containing 16ZBTB1600.0150.015
134Collagen type I alpha 1 chainCOL1A100.0150.015
135Endothelin receptor type AEDNRA00.0140.014
136Cellular communication network factor 1CCN100.0140.014
137Secreted protein acidic and cysteine richSPARC00.0140.014
138Glucagon like peptide 1 receptorGLP1R00.0140.014
139Cystatin CCST300.0140.014
140Intercellular adhesion molecule 1ICAM100.0140.014
142Tenascin CTNC00.0140.014
143PTEN-induced kinase 1PINK100.0140.014
145CCAAT enhancer binding protein betaCEBPB00.0120.012
146Acyl-coA thioesterase 1ACOT100.0120.012
147G protein-coupled bile acid receptor 1GPBAR100.0100.010
148Annexin A1ANXA100.0100.010
149Apolipoprotein L2APOL200.0080.008
150Natriuretic peptide BNPPB00.0080.008
151Leptin receptorLEPR00.0080.008
152Serum response factorSRF00.0080.008
153Heat shock protein family B (small) member 3HSPB300.0070.007
154Angiotensin II receptor type 1AGTR100.0070.007
155Protein phosphatase 5 catalytic subunitPPP5C00.0070.007

No.Pathway (No. of targets)

1.Signal transduction (63)
2.Immune system (47)
3.Metabolism of proteins (39)
4.Metabolism (31)
5.Gene expression (transcription) (25)
6.Hemostasis (23)
7.Disease (22)
8.Developmental biology (20)
9.Extracellular matrix organization (18)
10.Cellular responses to external stimuli (14)
11.Transport of small molecules (11)
12.Muscle contraction (11)
13.Vesicle-mediated transport (10)
14.Organelle biogenesis and maintenance (4)
15.Programmed cell death (4)
16.Autophagy (4)
17.Neuronal system (3)
18.Cell cycle (3)
19.Circadian clock (3)

mTOR was further investigated, and its association with heart diseases ranged from 0.0004 to 0.8588, which is the overall association score for 49 subtypes of heart diseases. mTOR had 0.1 and 0.8 overall association scores with DCM and hypertrophic cardiomyopathy, respectively (Table 3).

No.Heart diseaseAssociation score
Data types
Data types
Known drug
Data types
Data types
Animal model

1Heart disease0.000410.795500.141610.190280.8588
3Hypertrophic cardiomyopathy0.000000.772220.102140.000000.7978
4Heart failure0.000000.250000.052350.000000.2631
5Dilated cardiomyopathy0.000000.000000.075680.190280.2092
6Congestive heart failure0.000000.200000.026360.000000.2066
7Diastolic heart failure0.000000.200000.000000.000000.2000
8Barth syndrome0.000000.000000.000000.190280.1903
9Coronary heart disease0.000000.000000.120090.000000.1201
10Diabetic cardiomyopathy0.000000.100000.053910.000000.1135
11Coronary artery disease0.000000.000000.109610.000000.1096
12Systemic scleroderma0.000000.000000.099140.000000.0991
14Glycogen storage disease due to acid maltase deficiency0.000000.000000.083800.000000.0838
15Myocardial infarction0.000000.000000.064670.000000.0647
16Persistent truncus arteriosus0.000000.000000.061440.000000.0614
17Heart neoplasm0.000000.000000.061260.000000.0613
18Emery-Dreifuss muscular dystrophy0.000000.000000.057800.000000.0578
19Ischemia reperfusion injury0.000000.000000.057020.000000.0570
20Myocardial ischemia0.000000.000000.056580.000000.0566
21Carney complex0.000000.000000.054940.000000.0549
22Down syndrome0.000000.000000.054880.000000.0549
23Cardiac rhabdomyoma0.000000.000000.054750.000000.0547
24Autosomal dominant Emery-Dreifuss muscular dystrophy0.000000.000000.052800.000000.0528
25Polyarteritis nodosa0.000000.000000.043430.000000.0434
26Steinert myotonic dystrophy0.000000.000000.042730.000000.0427
27Acute myocardial infarction0.000000.000000.037980.000000.0380
28Cardiac arrhythmia0.000410.000000.037210.000000.0373
30Duchenne muscular dystrophy0.000000.000000.032530.000000.0325
31Gaucher disease0.000000.000000.032300.000000.0323
32Cardiac arrest0.000000.000000.028470.000000.0285
33Atrial fibrillation0.000000.000000.027200.000000.0272
34Aortic stenosis0.000000.000000.019100.000000.0191
35Acute coronary syndrome0.000000.000000.019000.000000.0190
36Sleep disorder0.000000.000000.018400.000000.0184
37Williams syndrome0.000000.000000.016400.000000.0164
38Supravalvular aortic stenosis0.000000.000000.016400.000000.0164
39Autoimmune myocarditis0.000000.000000.015600.000000.0156
40Friedreich ataxia0.000000.000000.014800.000000.0148
41Obstructive sleep apnea0.000000.000000.014800.000000.0148
42PHACE syndrome0.000000.000000.014400.000000.0144
43Glycogen storage disease due to LAMP-2 deficiency0.000000.000000.014400.000000.0144
44Idiopathic pulmonary arterial hypertension0.000000.000000.014000.000000.0140
45Fabry disease0.000000.000000.013400.000000.0134
46Becker muscular dystrophy0.000000.000000.008400.000000.0084
48Aortic coarctation0.000000.000000.006800.000000.0068
49Atrial flutter0.000410.000000.000000.000000.0004

mTOR is a serine/threonine-protein kinase playing as a central regulator of cellular metabolism, growth, and survival in response to hormone growth factor [27], nutrients, energy, and stress signals [28, 29]. According to UniPort, mTOR can be found in different subcellular locations including the membranes of endoplasmic reticulum, Golgi apparatus, outer mitochondrion, microsome, and lysosome; lysosome, cytoplasm, nucleus, and PML nuclear body. The RNA and protein expression levels of mTOR are present in several organs including the heart, e.g., the medium RNA and high protein levels of mTOR are expressed in the left ventricle, atrium, and coronary artery but not in the heart muscles (Figure 2).

3.1.2. Evidence on the Cardioprotection of G. lucidum

A total of 1731 articles were identified (Figure 3) and further divided into seven 5-year time periods. The first period ranged from 1985 to 1989, and the last period ranged from August 2018 to August 2019 (Figure 1). These articles were reviewed in the following three phases. First, 1571 articles remained after the duplicated ones were removed. Second, articles that did not satisfy the inclusion criteria based solely on their titles (remaining 1399 articles) and abstracts (remaining 59 articles) were excluded. Lastly, the remaining articles were scanned, and those that did not meet our inclusion criteria were excluded. After the initial screening of titles and abstracts, the 59 remaining articles were screened for the second time by two individual reviewers. Inclusion of full articles was agreed upon by two reviewers prior to data extraction. Finally, 33 studies were considered eligible for the review (Figure 2). In this section, the collected pieces of evidence were divided into two main parts, namely, the in vivo antioxidant of G. lucidum (14 studies, Table 4), in which the in vivo effect of antioxidant on the parameters related to OS was discussed, and the in vitro antioxidant of G. lucidum (19 studies, Table 5), in which the in vitro effect of antioxidant activities and possible molecular mechanisms was elaborated.

No.AnimalFormDosage (mg/kg)Antioxidant parametersBiological activityPathwayReferences

1CCl4-induced acute liver injury miceGLPS100 - 150NOS CYP2E1 MDA, GSHSuppressing free radical lipid peroxidationDecreasing of the protein expression levels of NLRP3, ASC, and caspase-1 in acute liver injury.
ASC (apoptosis-associated speck-like protein)
NLRP3 (NOD-like receptor 3)
GAPDH (glyceraldehyde-3-phosphate hydrogenase

2Croton oil applied skin edema in ratsEthanol extract of sporocarps500 and 1000 mg/kgAntiperoxidative, anti-inflammatory, and antimutagenic activitiesDirect anti-inflammatory and free radical scavenging properties of the extract[23]

3Photoreceptor cell lesions induced by N-methyl-N-nitrosourea (MNU) in female SD artsGanoderma spore lipid (GSL)500, 1000, 2000, and 4000 mg/kgExpressions of Bax, Bcl-xl, and caspase-3Improve A-wave amplitude (μv) decreased apoptosis levelsRegulate the expressions of Bax, Bcl-xl, and caspases-3, inhibiting MNU-induced rat, photoreceptor cell apoptosis, and protecting retinal function[30]

4A carotid-artery-ligation mouse modelGanoderma triterpenoid (GT)300 mg/kg/dayIntimal hyperplasia structural changes VCAM-1, TNF-α, and IL-6Atheroprotective propertiesEndothelin-1, von Willebrand factor, and monocyte chemoattractant protein-1[33]

5Swimming-induced oxidative stress in skeletal muscle miceGLPS50, 100, and 200 mg/kgSOD, GPX, and CAT activities as well as by the MDA levelsAttenuates exercise-induced oxidative stress in skeletal muscleIncreasing antioxidant enzyme activities and decrease the MDA levels. Protective effects against exhaustive exercise-induced oxidative stress[32]

6Rat gastric cancer modelGLPS400-800 mg/kg for 20 weeksSOD, CAT, and GSH-PxAntioxidantInduced the levels of serum IL-6 and TNF-α levels and increased the levels of serum IL-2, IL-4, and IL-10 in GLP-treated rats compared to gastric cancer model rats[37]

7BALB/c female miceGLPS i.p. daily50 mg/kg, 100 mg/kg, and 200 mg/kgSOD and GSH-PxAntioxidantImproved immunity in mice. Increased thymus and spleen index; improved SOD and GSH-Px contents in the mice body[31]

8T2DM ratsGLPS200, 400, and 800 mg × kg-1 for 16 weeksNO, SOD, MDA, GSH-Px, and CAT MDA in cardiac tissueAntioxidation in cardiac tissue of T2DM ratsReduce MDA in cardiac tissue and improve the myocardial ultrastructure[34]

9Male BALB/c mice (age19-21 months) (aged mice)Ethanolic extract of G. lucidum50 and 250 mg/kg, once daily for 15 daysGSH Mn-SOD, GPx, and GSTAntioxidant in heart tissuesElevated the levels of GSH as well as activities of MnSOD, GPx, and GST and decreased significantly the levels of lipid peroxidation, AOPP, and ROS. Improve the age-related decline of antioxidant status which was partly ascribed to free radical scavenging activity[38]

10B16 mouse melanomaMethanol extract containing total terpenoids (GLme) and a purified methanol extract containing mainly acidic terpenoids (GLpme)A daily i.p. injection of 100 mg/kg body weight (b.w.)Production of oxygen radical caspase-dependent apoptotic cell death-mediated production of reactive oxygen speciesAnticancerThe mechanism of antitumor activity of GLme comprised inhibition of cell proliferation and induction of caspase-dependent apoptotic cell death mediated by upregulated p53 and inhibited Bcl-2 expression[86]

11With non-insulin-dependent diabetes mellitus (NIDDM)Ganoderma lucidum spores250 mg/kg × d, for 10Xanthine oxidase (XOD), myeloperoxidase (MPO), and mitochondrial succinate dehydrogenase (SDH) in the testisReducing free radical-induceddamage to the testicular tissueProtect the testis of diabetic rats by reducing free radical-induced damage to the testicular tissue and enhancing the activity of SDH[35]

12Epididymal cells of type 2 diabetes ratsGanoderma lucidum spores (GLS)250 mg/kg × d, for 10 weeksContents of mitochondrial calcium & cytochrome CAntipoptosis induced by DMProtect epididymal cells and counteract their apoptosis in diabetic condition[36]

13Liver tissue of ratsGanoderma lucidum peptide27.1 μg/mLMalondialdehyde levelAntioxidantSubstantial antioxidant activity in the rat liver tissue homogenates and mitochondrial membrane peroxidation systems[87]

14Lupus miceGanoderma tsugae0.5 mg/kg/dayDecreased proteinuria, decreased serum levels of antidsDNA autoantibodyPrevention of autoantibodyPrevention of autoantibody formation[88]

No.FormConc.Chemical antioxidant testsBiological text of in vitroExp. parametersBiological activityPathwayReferences

1GLP0.5-3.0 mg/mLRS
=Scavenging of free radicals and reducing powerAntioxidantNM[89]
2G. lucidum and Egyptian Chlorella vulgarisCVE (63.5 μg/mL) was mixed with GLE (4.1 μg/mL)RS
Other tests
Lipopolysaccharide-stimulated white blood cellsNitric oxide, tumor necrosis factor- (TNF-) αAntioxidant and anti-inflammatoryDownregulate NF-κB[39]
3Polysaccharides in G. lucidum2 mg/mLRS
Other tests
NMRadical scavenging reducing powerAntioxidantNM[90]
4G. lucidum extract50 mgRS
Other tests
NMReducing powerAntimicrobial and antioxidantNM[40]
5Ganoderma lucidum G20.32 mgRS
Other tests
DNA protectionRadical scavenging reducing powerAntimicrobial and antioxidantNM[41]
6Protein extracts2–13 μg protein/mLAP
Other tests
DNA protectionRadical scavenging reducing powerAntioxidant, antibacterialNM[42]
7Polysaccharides extraction=FR
Other tests
MCF-7 breast cancer cell line and HeLa cellsRadical scavengingAntioxidant
8G. lucidum and G. resinaceum0.1–1 &
0–2.25 mg/mL
Other tests
In vitro cell lineRadical-scavenging chelating lipoxygenase assayAntiproliferative & antioxidantNM[44]
9Diff, organic solvent o G. lucidum1-200 μg/mLFR
Other tests
NMRadical scavenging, chelating lipid peroxidationAntioxidant
10Both aqueous and methanolic extracts0.2–30 mg/mL of extractionFR
Other tests
NMRadical scavenging, chelating lipid peroxidationAntioxidantNM[46]
11Low-molecular-weight β-1,3-glucan0–200 μg/mLAP
Other tests
Mouse monocyte-macrophage cell line, RAW 264.7H2O2-induced apoptosisAntioxidantAttenuating intracellular reactive oxygen species (ROS) and inhibiting sphingomyelinase (SMase) activity[51]
12Polysaccharides0.16-10 mg/mLFR
Other tests
NMRadical scavenging, chelating reducing powerAntioxidantNM[47]
13G. lucidumwater-soluble and water-insoluble80-1100 μg/mlFR
Other tests
Human uroepithelial cell (HUC-PC) cellsRadical scavenging, chelating reducing powerAntioxidantOxidative DNA damage. Lingzhi-induced apoptosis in bladder chemoprevention[48]
14Ganoderma lucidum polysaccharides0.1-0.6 mg/mlRSCCl-induced injury hepatocytes DNA protectionMDA, SOD, CYP3A, caspase-3, andcaspase-8Suppressing inflammatory responsesReduction of NF-κB activation inhibition of caspase-3, caspase-6, and caspase-9, indicating and suppression extrinsic-induced apoptosis[52]
15Ganoderic acid A10-80 lM/mLNMPancreatic cellsRadical scavenging
β-Catenin in Wnt signaling pathway[54]
16Aqueous extract of G. lucidum5-20 μLNMDNA protectionRadical scavengingAntioxidant
DNA repair
Enhancing reactivity of apurinic/apyrimidinic endonucleases (APE1) a major enzyme of base excision repair (BER)[91]
17Methanolic extract of G. lucidum65 & 130 μg/mLNMHuman gastric tumor cellsIncreased the formation of autophagosomesInduces autophagyIncreasing of the cellular levels of LC3-II and decreasing p62 (autophagy-related protein)[92]
18G. lucidum (GLPS) and G. sinense (GSPS)19–300 μg/mLNMRAW 264.7 mouse macrophage cellsNitric oxide secretion of cytokinesImmunomodulatoryPromoting macrophage phagocytosis, increasing their release of nitric oxide and cytokines interleukin- (IL-) 1a, IL-6, IL-10, and tumor necrosis factor-α[56]
19Proteopolysaccharide from G. lucidum2 - 10 μg/mLNMRAW264.7, a mouse macrophage cell lineNitrite production
Expression levels of cytokines
Activation the immune system by modulating cytokine production.NM[57]

NM = not mention; RS = radical scavenging; FR = ferric reducing; AP = antilipid peroxidation.
3.2. In Vivo Antioxidant Activity and Protective Effect of G. lucidum

According to 10 in vivo experimental studies, G. lucidum has antioxidant activities and protects against OS through four main factors in different tissues, such as the heart, liver, thymus, spleen, eyes, and skeletal muscles, and by regulating chemical-level OS parameters in blood circulation (Table 4). G. lucidum exhibits its antioxidant effects by increasing the antioxidant enzymes and inhibiting the enzymes involved in OS. G. lucidum also increases the activities of superoxide dismutase (SOD), glutathione-S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), mitochondrial succinate dehydrogenase (SDH), and Mn-SOD and reduces glutathione (GSH) levels. By contrast, G. lucidum decreases the activities of nitric oxide synthase (NOS), cytochrome P450 2E1 (CYP2E1), xanthine oxidase (XOD), and myeloperoxidase (MPO). G. lucidum also significantly decreases lipid peroxidation levels, advanced oxidation protein products (AOPPs), and malondialdehyde (MDA) levels.

The first factor is the four toxic substances, including CCl4-induced oxidative stress (OS) in the liver, croton oil produced OS in the skin through inflammation, N-methyl-N-nitrosourea (MNU) causing retinal photoreceptor cell lesions in the eyes, and 5-fluorouracil-induced OS in the thymus and spleen of mice. Oral administration of G. lucidum polysaccharides (GLPs) represses free radical lipid peroxidation induced by CCl4 to reduce the enzyme activities of NOS and CYP2E1. Significant inhibition of NOS and CYP2E1 activities and MDA and IL-1β levels was noted in liver tissues, and depleted levels of interleukin- (IL-) 1β, IL-18, IL-6, and tumor necrosis factor-α were found in serum. In CCl4-induced liver damage, highly reactive trichloromethyl free radicals are generated by the cytochrome P450 isozymes (P450s) of the endoplasmic reticulum [22]. Topical administration of G. lucidum ethanol extract inhibits the croton oil-induced lipid peroxidation in the skin of mice [23]. Ganoderma spore lipid (GSL) shows a protective effect on MNU-induced retina injury by inhibiting the related apoptosis to modulate the expression levels of Bax, Bcl-xl, and caspase-3 [30]. GLPs also exhibit an antioxidant effect in 5-fluorouracil-induced OS and improve SOD, an intracellular compound that protects against oxidative processes initiated by superoxide anion and GPx contents in the spleen and thymus of mice [31].

The second factor creates conditions in biological systems that can induce OS, such as exercise-like exhaustive swimming, which is OS induced in skeletal muscles, and a carotid artery ligation, which disturbs the flow-induced OS level of manganese-dependent superoxide dismutase (Mn-SOD) in blood vessels. GLPs show protective effects against comprehensive swimming-induced OS by improving the activities of antioxidant enzymes (SOD, GPx, and CAT) and decreasing the MDA levels in the skeletal muscle of mice [32]. Oral ganoderma triterpenoids (GTs) protect against disturbed flow-induced OS through carotid artery ligation, which leads to chronic OS and inflammation that are features of early atherogenesis in mice, and by preventing neointimal thickening 2 weeks after ligation. Early atherogenesis includes neointimal hyperplasia and endothelial dysfunction due to flow turbulence in the ligated artery as induced by OS. GTs alleviate OS and restore the atheroresistent status of endothelium by inhibiting endothelin-1 induction, von Willebrand factor, and monocyte chemoattractant protein-1 after 3-day ligation as atherogenic factors [33]. Inflammatory cytokines, OS-induced endothelial dysfunction, and chronic OS contribute to endothelial impairment and induces atherogenesis.

The third factor in OS includes diseases such as type II diabetes mellitus (DM) and cancer. In type II DM, the beneficial effects of G. lucidum on abnormal heart and testis and epididymal cells of rats with streptozotocin-induced type II DM were evaluated. GLPs improve the myocardial ultrastructure by reducing MDA, activating antioxidant enzymes (GSH-Px, CAT, SOD, and NO) in cardiac tissues, and reducing lipid peroxidation in type II DM rats [34]. G. lucidum spores protect the testis of rats with type II DM by substantially increasing the mitochondrial SDH and decreasing the activities of XOD and MPO [35]. G. lucidum spores protect epididymal cells and counteract their apoptosis that damages the mitochondria and disequilibrium of calcium homeostasis by reducing the amount of mitochondrial cytoplasm cytochrome C in type II DM rats [36]. GLP administration enhances the immunity and antioxidant activities in N-methyl-N9-nitro-nitrosoguanidine-induced gastric cancer in Wistar rats. GLP remarkably reduces the levels of serum IL-6 and TNF-α and increases the levels of serum IL-2, IL-4, and IL-10. In addition, GLP improves the levels of SOD, CAT, and GSH-Px in serum and gastric tissues [37].

The fourth factor involved in OS is aging. G. lucidum administration ameliorates the age-related decline of antioxidant status in aged mice, substantially elevates the activities of GST, Mn-SOD, GPx, and CAT, and reduces GSH. By contrast, lipid peroxidation, AOPP, and reactive oxygen species (ROS) are reduced [38] (Table 4).

3.3. In Vitro Antioxidant of G. lucidum and Its Possible Pathway

Chemical antioxidant tests consistently revealed the free radical scavenging activity of G. lucidum. Twelve studies reported the scavenging activity of G. lucidum for different free radicals including 2,2-diphenylpicrylhydrazyl radical (DPPH), 2,2-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS+), hydroxyl radical (HO), and hydrogen peroxide radicals (H2O2) [3949] (Table 5). G. lucidum also inhibits lipid peroxidation [23, 49]. In some studies, G. lucidum protects against DNA damage [41, 42, 50]. The results of chemical antioxidant tests regarding the antioxidant properties of G. lucidum are also in agreement with the cell-based antioxidant assays. G. lucidum shows free radical scavenging activity for H2O2 in RAW264.7 cells incubated with G. lucidum lipopolysaccharide and protects against H2O2-induced cell death [48]. G. lucidum also hinders sphingomyelinase activity in incubated RAW264.7 cells with lipopolysaccharide [51]. In addition, G. lucidum prevents lipid peroxidation in two cell models, namely, WBCs incubated with lipopolysaccharide to induce OS [39] and hepatocytes incubated with CCl4 to induce OS [52]. In both cell models, G. lucidum showed protection by elevating the antioxidant enzyme activity (SOD, GPx, and GR) and improving the GSH level. Moreover, G. lucidum protects macrophages in human monocytic cells incubated with lipopolysaccharide to stimulate NO production [53].

Wnt, Erk1/2, and NF-κB are the possible signaling pathways of G. lucidum that support its antioxidant and protective effects. A pancreatic cell study suggested β-catenin in the Wnt signaling pathway as a target of ganoderic acid A, thus leading to cell protection and effective scavenging of ROS [54]. The Wnt signaling pathways transfer the signals from extracellular to intercellular and are stimulated by the Wnt protein binding to the cytoplasmic family receptor, which occurs in downstream cell signaling and controls the transcription of genes. In the canonical Wnt pathway, β-catenin accumulates in the cytoplasm and is further translocated into the nucleus, and this phenomenon is widely recognized as a regulation marker of fat and glucose metabolism and β-catenin/Wnt signaling involved in insulin secretion [54]. In 2006, Thyagarajan and his colleagues mentioned that G. lucidum modulates Erk1/2 signaling and transcription factors AP-1 and NF-κB and downregulates c-Fos, whose expression can be induced by OS as the result of the inhibited OS-induced invasive behavior of breast cancer cells. A high H2O2 concentration (5 mM) can stimulate Erk1/2 signaling in MCF-7 cells [55].

In addition to its antioxidant activities, G. lucidum also exhibits an anti-inflammatory property and modulates the immune system. It can reverse LPS-induced inflammation by downregulating inflammatory mediators such as NF-κB, thus substantially inhibiting NOS and reducing NO level [39]. G. lucidum also modulates the immune system byregulating cytokine production in RAW264.7 macrophages [56, 57]. Moreover, it increases the formation of autophagosomes and controls proteins (Vps34, beclin 1, LC3-I, LC3-II, and p62) that induce autophagy in a gastric adenocarcinoma cell line. G. lucidum increases the cellular levels of LC3-II and decreases the cellular levels of p62 (Table 5).

4. Discussion

Among the 155 targets associated with DCM, mTOR, CPT1B, and CPT2 have the highest association. mTOR acts as a core regulator of cellular metabolism, growth, and survival in response to hormone growth factors, nutrients, energy, and stress signals. An animal study confirmed that streptozotocin-induced diabetes increases mTOR levels in rats [58]. mTOR can be found in different cellular locations including membrane, cytoplasm, and nucleus and different cellular organs (mitochondria, Golgi, and endoplasmic reticulum) and therefore is involved directly or indirectly in regulating the phosphorylation of at least 800 proteins (OPT.V19.11). mTOR functions through two distinct signaling complexes of mTORC1 and mTORC2 [59]. When activated, mTORC1 upregulates protein synthesis by phosphorylating the key regulators of mRNA translation and ribosome synthesis. mTORC1 also regulates protein synthesis [29], lipid synthesis [60], and mitochondrial biogenesis and stimulates the pyrimidine biosynthesis pathway through acute and delayed regulations. In acute regulation, mTORC1 stimulates pyrimidine biosynthesis through the ribosomal protein S6 kinase B1-mediated phosphorylation of biosynthetic enzyme carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase; these enzymes catalyze the first three steps in de novo pyrimidine synthesis [61]. In delayed regulation, mTORC1 stimulates pyrimidine biosynthesis through the transcriptional enhancement of the pentose phosphate pathway, which produces 5-phosphoribosyl-1-pyrophosphate, an allosteric activator of pyrimidine biosynthesis enzyme at a later step in the synthesis. In addition, mTORC1 regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through the phosphorylation and inhibition of MAF1 protein, a RNA polymerase III-repressor. When nutrients are available and mTOR kinase is active, MAF1 is hyperphosphorylated, and RNA polymerase III is engaged in the transcription [62]. Stress-induced MAF1 dephosphorylation resulted in nuclear localization, increased targeting of gene-bound RNA polymerase III, and decreased transcriptional readout [63, 64]. Moreover, mTORC1 is involved in the negative feedback regulation of autophagy on upstream growth factor signaling during microtubule regulation [6466].

mTORC2 regulates other cellular processes such as survival and organization of cytoskeleton, actin cytoskeleton [67], osteoclastogenesis, and circadian clock function. In a pressure-overloaded male mouse heart, mTORC2 maintains a contractile function [68]. In brown adipose tissues, mTOR complex 2 has a role in β3-adrenoceptor-stimulated glucose uptake by stimulating the translocation of newly synthesized GLUT1 to the plasma membrane, thereby increasing the glucose uptake [69]. mTOR complex 2 regulates the proper turnover of insulin receptor substrate-1 [70].

G. lucidum exhibits cardiac protection via its antioxidant properties through OS modulation. This systemic review of 33 studies has documented its antioxidant activities. At the molecular and cellular levels, OS is a key in diabetes-induced DCM [18]. The antioxidant effects of G. lucidum are facilitated by increasing the antioxidant enzymes and inhibiting the enzymes involved in OS [3335, 38]. G. lucidum consistently shows free radical scavenging activity against several free radicals including DPPH, ABTS+, HO, and H2O2. As confirmed by the in vitro (chemical and cell-based) antioxidant tests, G. lucidum inhibits lipid peroxidation and protects against DNA damage.

G. lucidum modulates several signal pathways including Erk1/2, NF-κB, and Wnt. Its antioxidant activity protects against inflammation and directly modulates immunity through scavenging radicals and through the oxidative signal pathways, thereby protecting the cells. These effects of G. lucidum may contribute to its positive influence on DCM.

DM is a state of persistent inflammation that upregulates mTOR at different levels of the myocardium, thereby influencing several signal pathways. The elevation of cellular cAMP levels disrupts phosphodiesterase-Rheb interaction, increases Rheb-mTOR interaction, and consequently leads to mTOR1 activation. Phosphodiesterase binds with Rheb and thereby inhibits the latter’s ability to activate mTOR [71]. Heart myocardium responds to high blood glucose by adapting its energy metabolism and using only fatty acids as a substrate, thus increasing OS through the upregulation of NADPH-oxidases, NO synthases [72], and reversible oxidative modifications for myocardial titin elastic protein [73]. mTOR upregulation and oxidative modification alter titin-based stiffness and titin isoform composition, thereby impairing myocardium contractility. The PI3K-Akt-mTOR kinase axis regulates the composition of titin isoform [73]. OS decreases NO levels, leading to the impairment of the NO-soluble guanylate cyclase- (sGC-) cyclic guanosine monophosphate- (cGMP-) protein kinase G (PKG) pathway, an important regulator of cardiac contractility [72]. Chronic intrude accumulation to high free fatty acids downregulates PPAR-α and impairs mTOR-PPAR-α, thereby causing mitochondrial dysfunction in rodent cardiomyocytes and further deteriorating cardiac function through the inhibition of fatty acid oxidation and increase in intracellular fat accumulation. PPAR-α is involved in the upregulation of carnitine palmitoyltransferase I, which increases the uptake of long-chain fatty acid in the mitochondria and facilitates the beta-oxidation of fatty acids. mTOR-PPAR-α axis modification can lead to inflammation [74] and immune dysfunction [75]. mTOR upregulation leads to the impaired response to adrenergic stimulation in DCM mice and further reduces heart contractility [58]. mTOR inhibition improves contractility via the chronic administration of PDE inhibitor in animals and patients with diabetes [76] and restores the impaired response to adrenergic stimulation in DCM mice [58]. G. lucidum shows its effects via several signal pathways such as Wnt, Erk1/2, and NF-κB pathway and consequently reduces the upregulated mTOR and its effects. mTOR is the main target of G. lucidum, and this finding supports its antioxidant and cardioprotective effects. G. lucidum inhibits the Wnt pathway [54] and may decrease the activity of mTOR via the Wnt/GSk/mTOR signal pathway. A pathologically stressed heart reactivates the Wnt signal pathway, which is modulated during left ventricular remodeling [77]. In heart cells, the Wnt pathway plays a role in the release of intracellular Ca2+ whose accumulation activates several Ca+2-sensitive proteins, fat and glucose metabolism, and cell fate decisions, such as renewal, differentiation, and apoptosis. Wnt dysregulation has an important role in cardiac diseases such as hypertrophy and fibrosis [78]. The Wnt pathway is important in the response to heart injuries leading to adverse effects on the heart [79] and is integrated with bioenergetic status to control mTOR activity [80]. Wnt is activated in late-stage inflammation of heart tissue [81]. G. lucidum suppresses Erk1/2 signaling [55] and consequently reduces the mTOR level. Erk1/2 signaling inhibits the TSC1/2 complex, which is the downregulator of mTOR, and thus activates mTOR [82]. The antioxidant properties of G. lucidum abolish the activation of the Erk pathway by OS. NADPH oxidase 2 is involved in Erk activation [83], and the inhibition of Erk/mTOR by G. lucidum also prevents NF-κB. mTOR activates NF-κB by phosphorylating the NF-κB p65 subunit, increasing p65 nuclear translocation, and activating gene transcription. With its anti-inflammatory effect, G. lucidum inhibits NF-κB via decreasing inflammatory mediators and cytokines such as TNF or IL-1, and innate immune response effectors activate NF-κB via the IKK complex through IκB protein phosphorylation with subsequent ubiquitination and degradation [84]. Inhibiting mTOR and NF-κB may improve the contractility of the heart, abolish the angiotensin II-induced hypertrophic response of cardiomyocytes [83], and prevent heart failure. A prolonged NF-κB activation promotes heart failure by evoking signals that induce chronic inflammation through the enhancement of cytokines including tumor necrosis factor, IL-1, and IL-6, commencing to endoplasmic reticulum stress responses and cell death [85].

Our results concluded that the antioxidant properties of G. lucidum and the cardioprotection of its polysaccharides may have a direct effect. Its free radical scavenging ability reduces OS and upregulates mTOR via several pathways including Wnt, Erk1/2, and NF-κB/IKK/TOR, thereby improving myocardium contractility (Figure 4). The anti-inflammatory properties may enhance the cAMP/cGMP/mTOR/PPAR pathway and its related protein or/and pathway and mitochondrial function, thus improving myocardium hemostasis. Further study is needed to identify the specific target of GLP in heart tissues.


ABTS+:2,2-azino-bis (3-ethylbenzthiazoline-6-sulphonic acid) radical
AOPP:Advanced oxidation protein products
Bax:BCL2 associated X, apoptosis regulator
Bcl-xl:B-cell lymphoma-extra large
BECN1:Beclin 1
cAMP:Cyclic adenosine monophosphate
CCl4:Carbon tetrachloride
c-Fos:A protooncogene
cGMP:Cyclic guanosine monophosphate
CPT1B and CPT2:Carnitine palmitoyltransferase 1B and 2
CYP2E1:Cytochrome P450 2E1
DCM:Diabetic cardiomyopathy
DM:Diabetic mellitus
DNA:Deoxyribonucleic acid
DPPH:2,2-diphenylpicrylhydrazyl radical
EMBL:European Molecular Biology Laboratory
Erk1/2:Extracellular signal-regulated kinase
GLPs:Ganoderma lucidum polysaccharides
GPx:Glutathione peroxidase
GR:Glutathione reductase
GSH:Reduced glutathione
GSH-Px:Glutathione peroxidase
GTs:Ganoderma triterpenoids
H2O2:Hydrogen peroxide radicals
HO:Hydroxyl radical
IL-6:Interleukin 6
LC3:Light chain 3
MAF1:Protein negative regulator of RNA polymerase III
MCF-7 cells:Breast cancer cell line
MDA:Malondialdehyde level
Mn-SOD:Manganese-superoxide dismutase
mTOR:Mammalian target of rapamycin
mTORC:mTOR complex
NF-κB:Nuclear factor-κB
NO:Nitrous oxide
NOS:Nitric oxide synthase
OS:Oxidative stress
OTP:Open Targets Platform
PKG:Protein kinase G
PML:Promyelocytic leukemia.

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

Hongbin Qiu and Shuqiu Wang performed the conceptualization; Fahmi Shaher and Mahfoudh A.M. Abdulghani did the methodology; Hisham AL-ward, Salem Baldi, and Yu Hu participated in the software; Shaobo Zhou, Mahfoudh A.M. Abdulghani, and Weiqun Wang contributed to the validation; Salem Baldi, Fahmi Shaher, and Mahfoudh A.M. Abdulghani performed the formal analysis; Yu Zhang and Yao Wei participated in the investigation; Shuqiu Wang contributed to acquiring resources; Fahmi Shaher helped in the data curation; Fahmi Shaher and Mahfoudh A.M. Abdulghani wrote and prepared the original draft; Shaobo Zhou wrote, reviewed, and edited the manuscript; Mahfoudh A.M. Abdulghani and Fahmi Shaher performed the visualization; Hongbin Qiu supervised the study; Shuqiu Wang did the project administration; Shuqiu Wang helped in funding acquisition. Authorship must be limited to those who have contributed substantially to the work reported.


This research was funded by the Jiamusi University, Basic Medicine College team, under grant number JDXKTD-2019002.

Supplementary Materials

Supplementary Table 1: association sore of 309 targets associated with diabetic cardiomyopathy in 30 recorded tissues. Supplementary Table 2: thirty-two tissue organs expressed 309 targets and types of pathways. (Supplementary Materials)


  1. S. Raghavan, J. L. Vassy, Y. L. Ho et al., “Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults,” Journal of the American Heart Association, vol. 8, no. 4, article e011295, 2019. View at: Publisher Site | Google Scholar
  2. D. Glovaci, W. Fan, and N. D. Wong, “Epidemiology of diabetes mellitus and cardiovascular disease,” Current Cardiology Reports, vol. 21, no. 4, p. 21, 2019. View at: Publisher Site | Google Scholar
  3. M. C. Bertoluci and V. Z. Rocha, “Cardiovascular risk assessment in patients with diabetes,” Diabetology & Metabolic Syndrome, vol. 9, no. 1, p. 25, 2017. View at: Publisher Site | Google Scholar
  4. L. J. Williams, B. G. Nye, and A. R. Wende, “Diabetes-related cardiac dysfunction,” Endocrinology and Metabolism, vol. 32, no. 2, pp. 171–179, 2017. View at: Publisher Site | Google Scholar
  5. S. Karuranga, J. da Rocha Fernandes, Y. Huang, and B. Malanda, IDF Diabetes Atlas, IDF, Brussels, 8th edition, 2017.
  6. P. K. Battiprolu, T. G. Gillette, Z. V. Wang, S. Lavandero, and J. A. Hill, “Diabetic cardiomyopathy: mechanisms and therapeutic targets,” Drug Discovery Today: Disease Mechanisms, vol. 7, no. 2, pp. e135–e143, 2010. View at: Publisher Site | Google Scholar
  7. G. L. Booth, M. K. Kapral, K. Fung, and J. V. Tu, “Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study,” The Lancet, vol. 368, no. 9529, pp. 29–36, 2006. View at: Publisher Site | Google Scholar
  8. S. G. Wannamethee, A. G. Shaper, P. H. Whincup, L. Lennon, and N. Sattar, “Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors,” Archives of Internal Medicine, vol. 171, no. 5, pp. 404–410, 2011. View at: Publisher Site | Google Scholar
  9. S. Boudina and E. D. Abel, “Diabetic cardiomyopathy revisited,” Circulation, vol. 115, no. 25, pp. 3213–3223, 2007. View at: Publisher Site | Google Scholar
  10. C. H. Mandavia, A. R. Aroor, V. G. DeMarco, and J. R. Sowers, “Molecular and metabolic mechanisms of cardiac dysfunction in diabetes,” Life Sciences, vol. 92, no. 11, pp. 601–608, 2013. View at: Publisher Site | Google Scholar
  11. P. Poirier, P. Bogaty, C. Garneau, L. Marois, and J. G. Dumesnil, “Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy,” Diabetes Care, vol. 24, no. 1, pp. 5–10, 2001. View at: Publisher Site | Google Scholar
  12. L. Ernande, C. Bergerot, E. R. Rietzschel et al., “Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy?” Journal of the American Society of Echocardiography, vol. 24, no. 11, pp. 1268–1275.e1, 2011. View at: Publisher Site | Google Scholar
  13. S. Xi, G. Zhou, X. Zhang, W. Zhang, L. Cai, and C. Zhao, “Protective effect of total aralosides of Aralia elata (Miq) Seem (TASAES) against diabetic cardiomyopathy in rats during the early stage, and possible mechanisms,” Experimental & Molecular Medicine, vol. 41, no. 8, pp. 538–547, 2009. View at: Publisher Site | Google Scholar
  14. X. Sun, R. C. Chen, Z. H. Yang et al., “Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of oxidative stress and cell apoptosis,” Food and Chemical Toxicology, vol. 63, pp. 221–232, 2014. View at: Publisher Site | Google Scholar
  15. G. Zhou, C. Li, and L. Cai, “Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway,” The American Journal of Pathology, vol. 165, no. 6, pp. 2033–2043, 2004. View at: Publisher Site | Google Scholar
  16. L. Pereira, J. Matthes, I. Schuster et al., “Mechanisms of [Ca2+] i transient decrease in cardiomyopathy of db/db type 2 diabetic mice,” Diabetes, vol. 55, no. 3, pp. 608–615, 2006. View at: Publisher Site | Google Scholar
  17. M. Sulaiman, M. J. Matta, N. R. Sunderesan, M. P. Gupta, M. Periasamy, and M. Gupta, “Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 3, pp. H833–H843, 2010. View at: Publisher Site | Google Scholar
  18. S. W. Schaffer, C. J. Jong, and M. Mozaffari, “Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited,” Vascular Pharmacology, vol. 57, no. 5-6, pp. 139–149, 2012. View at: Publisher Site | Google Scholar
  19. S. Wachtel-Galor, J. Yuen, J. A. Buswell, and I. F. Benzie, “Ganoderma lucidum (Lingzhi or Reishi),” in Herbal Medicine: Biomolecular and Clinical Aspects, CRC Press/Taylor & Francis, 2nd edition, 2011. View at: Google Scholar
  20. O. Kwon, C.-S. Lee, and Y.-J. Park, “SNP and SCAR markers for specific discrimination of antler-shaped Ganoderma lucidum,” Microorganisms, vol. 7, no. 1, p. 12, 2019. View at: Publisher Site | Google Scholar
  21. X.-C. Wang, R.-J. Xi, Y. Li, D.-M. Wang, and Y.-J. Yao, “The species identity of the widely cultivated Ganoderma,‘G. lucidum’(Ling-zhi), in China,” PLoS One, vol. 7, no. 7, 2012. View at: Google Scholar
  22. Y.-S. Chen, Q. Z. Chen, Z. J. Wang, and C. Hua, “Anti-inflammatory and hepatoprotective effects of Ganoderma lucidum polysaccharides against carbon tetrachloride-induced liver injury in Kunming mice,” Pharmacology, vol. 103, no. 3-4, pp. 143–150, 2019. View at: Publisher Site | Google Scholar
  23. B. Lakshmi, T. A. Ajith, N. Sheena, N. Gunapalan, and K. K. Janardhanan, “Antiperoxidative, anti-inflammatory, and antimutagenic activities of ethanol extract of the mycelium of Ganoderma lucidum occurring in South India,” Teratogenesis, Carcinogenesis, and Mutagenesis, vol. 23, no. S1, pp. 85–97, 2003. View at: Publisher Site | Google Scholar
  24. G. Koscielny, P. An, D. Carvalho-Silva et al., “Open Targets: a platform for therapeutic target identification and validation,” Nucleic Acids Research, vol. 45, no. D1, pp. D985–D994, 2017. View at: Publisher Site | Google Scholar
  25. D. Carvalho-Silva, A. Pierleoni, M. Pignatelli et al., “Open Targets Platform: new developments and updates two years on,” Nucleic Acids Research, vol. 47, no. D1, pp. D1056–D1065, 2019. View at: Publisher Site | Google Scholar
  26. A. Liberati, “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” Annals of internal medicine, vol. 151, no. 4, p. W, 2009. View at: Publisher Site | Google Scholar
  27. P. P. Hsu, S. A. Kang, J. Rameseder et al., “The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling,” Science, vol. 332, no. 6035, pp. 1317–1322, 2011. View at: Publisher Site | Google Scholar
  28. D.-H. Kim, D. D. Sarbassov, S. M. Ali et al., “mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery,” Cell, vol. 110, no. 2, pp. 163–175, 2002. View at: Publisher Site | Google Scholar
  29. J. Brugarolas, K. Lei, R. L. Hurley et al., “Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex,” Genes & Development, vol. 18, no. 23, pp. 2893–2904, 2004. View at: Publisher Site | Google Scholar
  30. Y. Gao, X. G. Deng, Q. N. Sun, and Z. Q. Zhong, “Ganoderma spore lipid inhibits N-methyl-N-nitrosourea-induced retinal photoreceptor apoptosis in vivo,” Experimental Eye Research, vol. 90, no. 3, pp. 397–404, 2010. View at: Publisher Site | Google Scholar
  31. J. Wang, Y. Wang, X. Liu, Y. Yuan, and T. Yue, “Free radical scavenging and immunomodulatory activities of Ganoderma lucidum polysaccharides derivatives,” Carbohydrate Polymers, vol. 91, no. 1, pp. 33–38, 2013. View at: Publisher Site | Google Scholar
  32. Z. Zhonghui, Z. Xiaowei, and F. Fang, “Ganoderma lucidum polysaccharides supplementation attenuates exercise-induced oxidative stress in skeletal muscle of mice,” Saudi journal of biological sciences, vol. 21, no. 2, pp. 119–123, 2014. View at: Publisher Site | Google Scholar
  33. P.-L. Hsu, Y. C. Lin, H. Ni, and F. E. Mo, “Ganoderma triterpenoids exert antiatherogenic effects in mice by alleviating disturbed flow-induced oxidative stress and inflammation,” Oxidative Medicine and Cellular Longevity, vol. 2018, 11 pages, 2018. View at: Publisher Site | Google Scholar
  34. H. Xue, J. Qiao, G. Meng et al., “Effect of Ganoderma lucidum polysaccharides on hemodynamic and antioxidation in T2DM rats,” China journal of Chinese materia medica, vol. 35, no. 3, pp. 339–343, 2010. View at: Publisher Site | Google Scholar
  35. S. Wang, W. B. Qin, Y. M. Kang et al., “Intervention effect of ganoderma lucidum spores on the changes of XOD, MPO and SDH in the testis tissue of NIDDM rats,” National Journal of Andrology, vol. 14, no. 9, pp. 792–795, 2008. View at: Google Scholar
  36. X. Ma, C. F. Zhou, S. Q. Wang et al., “Effects of ganoderma lucidum spores on mitochondrial calcium ion and cytochrome C in epididymal cells of type 2 diabetes rats,” National Journal of Andrology, vol. 13, no. 5, pp. 400–402, 2007. View at: Google Scholar
  37. K. Pan, Q. Jiang, G. Liu, X. Miao, and D. Zhong, “Optimization extraction of Ganoderma lucidum polysaccharides and its immunity and antioxidant activities,” International Journal of Biological Macromolecules, vol. 55, pp. 301–306, 2013. View at: Publisher Site | Google Scholar
  38. N. P. Sudheesh, T. A. Ajith, V. Ramnath, and K. K. Janardhanan, “Therapeutic potential of _Ganoderma lucidum_ (Fr.) P. Karst. against the declined antioxidant status in the mitochondria of post-mitotic tissues of aged mice,” Clinical Nutrition, vol. 29, no. 3, pp. 406–412, 2010. View at: Publisher Site | Google Scholar
  39. M. M. Abu-Serie, N. H. Habashy, and W. E. Attia, “In vitro evaluation of the synergistic antioxidant and anti-inflammatory activities of the combined extracts from Malaysian Ganoderma lucidum and Egyptian Chlorella vulgaris,” BMC Complementary and Alternative Medicine, vol. 18, no. 1, p. 154, 2018. View at: Publisher Site | Google Scholar
  40. S. Sharif, M. Shahid, M. Mushtaq, S. Akram, and A. Rashid, “Wild mushrooms: a potential source of nutritional and antioxidant attributes with acceptable toxicity,” Preventive nutrition and food science, vol. 22, no. 2, pp. 124–130, 2017. View at: Publisher Site | Google Scholar
  41. R. Sarnthima, S. Khammaung, and P. Sa-ard, “Culture broth of Ganoderma lucidum exhibited antioxidant, antibacterial and α-amylase inhibitory activities,” Journal of Food Science and Technology, vol. 54, no. 11, pp. 3724–3730, 2017. View at: Publisher Site | Google Scholar
  42. P. Sa-ard, R. Sarnthima, S. Khammuang, and W. Kanchanarach, “Antioxidant, antibacterial and DNA protective activities of protein extracts from Ganoderma lucidum,” Journal of Food Science and Technology, vol. 52, no. 5, pp. 2966–2973, 2015. View at: Publisher Site | Google Scholar
  43. P. Chen, Y. Yong, Y. Gu, Z. Wang, S. Zhang, and L. Lu, “Comparison of antioxidant and antiproliferation activities of polysaccharides from eight species of medicinal mushrooms,” International journal of medicinal mushrooms, vol. 17, no. 3, pp. 287–295, 2015. View at: Publisher Site | Google Scholar
  44. R. Saltarelli, P. Ceccaroli, M. Buffalini et al., “Biochemical characterization and antioxidant and antiproliferative activities of different Ganoderma collections,” Journal of Molecular Microbiology and Biotechnology, vol. 25, no. 1, pp. 16–25, 2015. View at: Publisher Site | Google Scholar
  45. G. Tel, M. Ozturk, M. E. Duru, and A. Turkoglu, “Antioxidant and anticholinesterase activities of five wild mushroom species with total bioactive contents,” Pharmaceutical Biology, vol. 53, no. 6, pp. 824–830, 2014. View at: Google Scholar
  46. P. Rani, M. R. Lal, U. Maheshwari, and S. Krishnan, “Antioxidant potential of lingzhi or reishi medicinal mushroom, Ganoderma lucidum (higher basidiomycetes) cultivated on Artocarpus heterophyllus sawdust substrate in India,” International Journal of Medicinal Mushrooms, vol. 17, no. 12, pp. 1171–1177, 2015. View at: Publisher Site | Google Scholar
  47. W. Liu, H. Wang, X. Pang, W. Yao, and X. Gao, “Characterization and antioxidant activity of two low-molecular-weight polysaccharides purified from the fruiting bodies of Ganoderma lucidum,” International Journal of Biological Macromolecules, vol. 46, no. 4, pp. 451–457, 2010. View at: Publisher Site | Google Scholar
  48. J. Yuen and M. Gohel, “The dual roles of Ganoderma antioxidants on urothelial cell DNA under carcinogenic attack,” Journal of Ethnopharmacology, vol. 118, no. 2, pp. 324–330, 2008. View at: Publisher Site | Google Scholar
  49. J.-L. Mau, H.-C. Lin, and C.-C. Chen, “Antioxidant properties of several medicinal mushrooms,” Journal of Agricultural and Food Chemistry, vol. 50, no. 21, pp. 6072–6077, 2002. View at: Publisher Site | Google Scholar
  50. K. C. Kim and I. Kim, “Ganoderma lucidum extract protects DNA from strand breakage caused by hydroxyl radical and UV irradiation,” International Journal of Molecular Medicine, vol. 4, no. 3, pp. 273–277, 1999. View at: Google Scholar
  51. P.-F. Kao, S.-H. Wang, W.-T. Hung, Y.-H. Liao, C.-M. Lin, and W.-B. Yang, “Structural Characterization and Antioxidative Activity of Low-Molecular- Weights Beta-1,3-Glucan from the Residue of Extracted Ganoderma lucidum Fruiting Bodies,” Journal of Biomedicine and Biotechnology, vol. 2012, 8 pages, 2012. View at: Publisher Site | Google Scholar
  52. Y.-J. Liu, J. L. du, L. P. Cao et al., “Anti-inflammatory and hepatoprotective effects of Ganoderma lucidum polysaccharides on carbon tetrachloride-induced hepatocyte damage in common carp (Cyprinus carpio L.),” International Immunopharmacology, vol. 25, no. 1, pp. 112–120, 2015. View at: Publisher Site | Google Scholar
  53. C. W. H. Woo, R. Y. K. Man, Y. L. Siow et al., “Ganoderma lucidum inhibits inducible nitric oxide synthase expression in macrophages,” Molecular and Cellular Biochemistry, vol. 275, no. 1-2, pp. 165–171, 2005. View at: Publisher Site | Google Scholar
  54. B. S. Gill and S. Kumar, “Ganoderic acid A targeting β-catenin in Wnt signaling pathway: in silico and in vitro study,” Interdisciplinary Sciences: Computational Life Sciences, vol. 10, no. 2, pp. 233–243, 2018. View at: Google Scholar
  55. A. Thyagarajan, J. Jiang, A. Hopf, J. Adamec, and D. Sliva, “Inhibition of oxidative stress-induced invasiveness of cancer cells by Ganoderma lucidum is mediated through the suppression of interleukin-8 secretion,” International Journal of Molecular Medicine, vol. 18, no. 4, pp. 657–664, 2006. View at: Google Scholar
  56. L.-Z. Meng, J. Xie, G. P. Lv et al., “A comparative study on immunomodulatory activity of polysaccharides from two official species of Ganoderma (Lingzhi),” Nutrition and Cancer, vol. 66, no. 7, pp. 1124–1131, 2014. View at: Publisher Site | Google Scholar
  57. Z. Ji, Q. Tang, J. Zhang, Y. Yang, W. Jia, and Y. Pan, “Immunomodulation of RAW264. 7 macrophages by GLIS, a proteopolysaccharide from Ganoderma lucidum,” Journal of Ethnopharmacology, vol. 112, no. 3, pp. 445–450, 2007. View at: Publisher Site | Google Scholar
  58. T. M. West, Q. Wang, B. Deng et al., “Phosphodiesterase 5 associates with β2 adrenergic receptor to modulate cardiac function in type 2 diabetic hearts,” Journal of the American Heart Association, vol. 8, no. 15, article e012273, 2019. View at: Publisher Site | Google Scholar
  59. E. Jacinto, R. Loewith, A. Schmidt et al., “Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive,” Nature Cell Biology, vol. 6, no. 11, pp. 1122–1128, 2004. View at: Publisher Site | Google Scholar
  60. T. Porstmann, C. R. Santos, B. Griffiths et al., “SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth,” Cell Metabolism, vol. 8, no. 3, pp. 224–236, 2008. View at: Publisher Site | Google Scholar
  61. A. M. Robitaille, S. Christen, M. Shimobayashi et al., “Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis,” Science, vol. 339, no. 6125, pp. 1320–1323, 2013. View at: Publisher Site | Google Scholar
  62. A. A. Michels, A. M. Robitaille, D. Buczynski-Ruchonnet et al., “mTORC1 directly phosphorylates and regulates human MAF1,” Molecular and Cellular Biology, vol. 30, no. 15, pp. 3749–3757, 2010. View at: Publisher Site | Google Scholar
  63. A. Orioli, V. Praz, P. Lhôte, and N. Hernandez, “Human MAF1 targets and represses active RNA polymerase III genes by preventing recruitment rather than inducing long-term transcriptional arrest,” Genome Research, vol. 26, no. 5, pp. 624–635, 2016. View at: Publisher Site | Google Scholar
  64. M. Holczer, B. Hajdú, T. Lőrincz, A. Szarka, G. Bánhegyi, and O. Kapuy, “A double negative feedback loop between mTORC1 and AMPK kinases guarantees precise autophagy induction upon cellular stress,” International Journal of Molecular Sciences, vol. 20, no. 22, p. 5543, 2019. View at: Publisher Site | Google Scholar
  65. I. Koren, E. Reem, and A. Kimchi, “DAP1, a novel substrate of mTOR, negatively regulates autophagy,” Current biology, vol. 20, no. 12, pp. 1093–1098, 2010. View at: Publisher Site | Google Scholar
  66. D.-Y. Zhao, D. D. Yu, L. Ren, and G. R. Bi, “Ligustilide protects PC12 cells from oxygen-glucose deprivation/reoxygenation-induced apoptosis via the LKB1-AMPK-mTOR signaling pathway,” Neural Regeneration Research, vol. 15, no. 3, pp. 473–481, 2020. View at: Publisher Site | Google Scholar
  67. D. D. Sarbassov, S. M. Ali, D.-H. Kim et al., “Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton,” Current biology, vol. 14, no. 14, pp. 1296–1302, 2004. View at: Publisher Site | Google Scholar
  68. P. Shende, L. Xu, C. Morandi et al., “Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy,” Cardiovascular Research, vol. 109, no. 1, pp. 103–114, 2015. View at: Google Scholar
  69. J. M. Olsen, M. Sato, O. S. Dallner et al., “Glucose uptake in brown fat cells is dependent on mTOR complex 2–promoted GLUT1 translocation,” Journal of Cell Biology, vol. 207, no. 3, pp. 365–374, 2014. View at: Publisher Site | Google Scholar
  70. S. J. Kim, M. A. DeStefano, W. J. Oh et al., “mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8,” Molecular Cell, vol. 48, no. 6, pp. 875–887, 2012. View at: Publisher Site | Google Scholar
  71. H. W. Kim, S. H. Ha, M. N. Lee et al., “Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4D,” Molecular and Cellular Biology, vol. 30, no. 22, pp. 5406–5420, 2010. View at: Publisher Site | Google Scholar
  72. C. Mátyás, B. T. Németh, A. Oláh et al., “Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes,” European Journal of Heart Failure, vol. 19, no. 3, pp. 326–336, 2017. View at: Publisher Site | Google Scholar
  73. F. Koser, C. Loescher, and W. A. Linke, “Posttranslational modifications of titin from cardiac muscle: how, where, and what for?” The FEBS Journal, vol. 286, no. 12, pp. 2240–2260, 2019. View at: Publisher Site | Google Scholar
  74. G. Sarnelli, A. D’Alessandro, T. Iuvone et al., “Palmitoylethanolamide modulates inflammation-associated vascular endothelial growth factor (VEGF) signaling via the Akt/mTOR pathway in a selective peroxisome proliferator-activated receptor alpha (PPAR-α)-dependent manner,” PLoS One, vol. 11, no. 5, article e0156198, 2016. View at: Publisher Site | Google Scholar
  75. R. Maile, W. H. Stepp, T. Eitas, and B. A. Cairns, The Mammalian Target of Rapamycin (mTOR)/Peroxisome Proliferator-Activated Receptor γ (PPARγ) axis drives immune dysfunction and outcome after burn injury, 2018.
  76. A. Das, D. Durrant, F. N. Salloum, L. Xi, and R. C. Kukreja, “PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer,” Pharmacology & Therapeutics, vol. 147, pp. 12–21, 2015. View at: Publisher Site | Google Scholar
  77. M. W. Bergmann, “WNT signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development,” Circulation Research, vol. 107, no. 10, pp. 1198–1208, 2010. View at: Publisher Site | Google Scholar
  78. A. Deb, “Cell–cell interaction in the heart via Wnt/β-catenin pathway after cardiac injury,” Cardiovascular Research, vol. 102, no. 2, pp. 214–223, 2014. View at: Publisher Site | Google Scholar
  79. H. Haybar, E. Khodadi, and S. Shahrabi, “Wnt/β-catenin in ischemic myocardium: interactions and signaling pathways as a therapeutic target,” Heart Failure Reviews, vol. 24, no. 3, pp. 411–419, 2019. View at: Publisher Site | Google Scholar
  80. K. Inoki, H. Ouyang, T. Zhu et al., “TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth,” Cell, vol. 126, no. 5, pp. 955–968, 2006. View at: Publisher Site | Google Scholar
  81. O. Aisagbonhi, M. Rai, S. Ryzhov, N. Atria, I. Feoktistov, and A. K. Hatzopoulos, “Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition,” Disease Models & Mechanisms, vol. 4, no. 4, pp. 469–483, 2011. View at: Publisher Site | Google Scholar
  82. L. Ma, Z. Chen, H. Erdjument-Bromage, P. Tempst, and P. P. Pandolfi, “Phosphorylation and functional inactivation of TSC2 by Erk,” Cell, vol. 121, no. 2, pp. 179–193, 2005. View at: Publisher Site | Google Scholar
  83. Y. Li, T. Ha, X. Gao et al., “NF-κB activation is required for the development of cardiac hypertrophy in vivo,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 287, no. 4, pp. H1712–H1720, 2004. View at: Google Scholar
  84. M. Hayden and S. Ghosh, “Signaling to NF-κB,” Genes & development, vol. 18, no. 18, pp. 2195–2224, 2004. View at: Publisher Site | Google Scholar
  85. J. W. Gordon, J. A. Shaw, and L. A. Kirshenbaum, “Multiple facets of NF-κB in the heart: to be or not to NF-κB,” Circulation Research, vol. 108, no. 9, pp. 1122–1132, 2011. View at: Publisher Site | Google Scholar
  86. L. M. Harhaji Trajković, S. A. Mijatović, D. D. Maksimović-Ivanić et al., “Anticancer properties of Ganoderma lucidum methanol extracts in vitro and in vivo,” Nutrition and Cancer, vol. 61, no. 5, pp. 696–707, 2009. View at: Publisher Site | Google Scholar
  87. J. Sun, H. He, and B. J. Xie, “Novel antioxidant peptides from fermented mushroom Ganoderma lucidum,” Journal of Agricultural and Food Chemistry, vol. 52, no. 21, pp. 6646–6652, 2004. View at: Publisher Site | Google Scholar
  88. N.-S. Lai, R.-H. Lin, R.-S. Lai, U.-C. Kun, and S.-C. Leu, “Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice with an ancient Chinese herb Ganoderma tsugae,” Lupus, vol. 10, no. 7, pp. 461–465, 2016. View at: Publisher Site | Google Scholar
  89. X. Zeng, P. Li, X. Chen et al., “Effects of deproteinization methods on primary structure and antioxidant activity of Ganoderma lucidum polysaccharides,” International Journal of Biological Macromolecules, vol. 126, pp. 867–876, 2019. View at: Publisher Site | Google Scholar
  90. X. Tan, J. Sun, Z. Xu et al., “Effect of heat stress on production and in-vitro antioxidant activity of polysaccharides in Ganoderma lucidum,” Bioprocess and Biosystems Engineering, vol. 41, no. 1, pp. 135–141, 2018. View at: Publisher Site | Google Scholar
  91. B. Kumari, P. Das, and R. Kumari, “Accelerated processing of solitary and clustered abasic site DNA damage lesions by APE1 in the presence of aqueous extract of Ganoderma lucidum,” Journal of Biosciences, vol. 41, no. 2, pp. 265–275, 2016. View at: Publisher Site | Google Scholar
  92. F. Reis, R. Lima, P. Morales, I. Ferreira, and M. Vasconcelos, “Methanolic extract of Ganoderma lucidum induces autophagy of AGS human gastric tumor cells,” Molecules, vol. 20, no. 10, pp. 17872–17882, 2015. View at: Publisher Site | Google Scholar

Copyright © 2020 Fahmi Shaher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.